Enterprise Bank & Trust Co reduced its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 2.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 9,027 shares of the conglomerate’s stock after selling 181 shares during the period. Enterprise Bank & Trust Co’s holdings in Danaher were worth $2,072,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in DHR. FMR LLC grew its holdings in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Danaher by 2.4% during the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after acquiring an additional 139,989 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Danaher by 3.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after acquiring an additional 148,251 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Danaher by 2.6% in the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after acquiring an additional 116,299 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Price Performance
NYSE DHR traded up $4.45 on Monday, reaching $239.52. 2,130,737 shares of the stock traded hands, compared to its average volume of 2,747,398. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market cap of $173.00 billion, a price-to-earnings ratio of 45.71, a P/E/G ratio of 4.32 and a beta of 0.83. The firm’s fifty day simple moving average is $235.67 and its 200 day simple moving average is $253.73. Danaher Co. has a 12 month low of $222.53 and a 12 month high of $281.70.
Danaher Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s payout ratio is presently 20.61%.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the company. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Stephens restated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, KeyCorp increased their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.
Check Out Our Latest Report on Danaher
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What does consumer price index measure?
- Delta Can Fly to New Highs in 2025; Here’s Why
- What is a Secondary Public Offering? What Investors Need to Know
- Snowflake Stock: Bullish Upgrades Demand Investors’ Attention
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.